Monday 25 June 2018
Contact US    |    Archive
Reuters
4 months ago

Gilead wins reversal of $2.54 bln hepatitis C drug patent verdict

Feb 17 (Reuters) - A federal judge in Delaware has overturned a jury s verdict requiring Gilead Sciences Inc to pay a record $2.54 billion because its hepatitis C drugs Sovaldi and Harvoni infringed a patent held by rival Merck and Co Inc.

Read on the original site


هذه الصفحة هي مجرد قاریء تلقائي للأخبار باستخدام خدمة الـ RSS و بأن نشر هذه الأخبار هنا لاتعني تأییدها علی الإطلاق.
Hashtags:   

Gilead

 | 

wins

 | 

reversal

 | 

bln

 | 

hepatitis

 | 

drug

 | 

patent

 | 

verdict

 | 
Most Popular (6 hours)

Most Popular (24 hours)

Most Popular (a week)

Categories - Countries
All News
USA